KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Payables (2016 - 2025)

Historic Payables for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $253.7 million.

  • West Pharmaceutical Services' Payables rose 601.76% to $253.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $253.7 million, marking a year-over-year increase of 601.76%. This contributed to the annual value of $253.7 million for FY2025, which is 601.76% up from last year.
  • Per West Pharmaceutical Services' latest filing, its Payables stood at $253.7 million for Q4 2025, which was up 601.76% from $255.8 million recorded in Q3 2025.
  • West Pharmaceutical Services' Payables' 5-year high stood at $255.8 million during Q3 2025, with a 5-year trough of $188.9 million in Q3 2022.
  • For the 5-year period, West Pharmaceutical Services' Payables averaged around $226.4 million, with its median value being $226.4 million (2024).
  • Its Payables has fluctuated over the past 5 years, first surged by 2938.57% in 2021, then plummeted by 905.15% in 2022.
  • Over the past 5 years, West Pharmaceutical Services' Payables (Quarter) stood at $232.2 million in 2021, then decreased by 7.24% to $215.4 million in 2022, then rose by 12.53% to $242.4 million in 2023, then dropped by 1.28% to $239.3 million in 2024, then rose by 6.02% to $253.7 million in 2025.
  • Its last three reported values are $253.7 million in Q4 2025, $255.8 million for Q3 2025, and $239.0 million during Q2 2025.